Sugi Predict

Sugi Predict / Compounds / SCHEMBL4404523

SCHEMBL4404523

SCHEMBL4404523

Nc1ncc(-c2ccn(C3CCNCC3)c2)nc1-c1nnnn1-c1cccc(F)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 7/20 0.38
▸ FGFR2 P21802 7/20 0.38
▸ FGFR3 P22607 7/20 0.38
▸ ATR Q13535 3/20 0.35
▸ MAP4K3 Q8IVH8 3/20 0.35
▸ MAPK14 Q16539 3/20 0.34
▸ MAPK13 O15264 1/20 0.34
▸ RIPK2 O43353 1/20 0.34
▸ DYRK3 O43781 1/20 0.34
▸ PRKD3 O94806 1/20 0.34
▸ MAP4K4 O95819 1/20 0.34
▸ PRKCG P05129 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ LYN P07948 1/20 0.34
▸ RET P07949 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ PRKACA P17612 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406272 0.87 FGFR1 (0.51) FGFR1FGFR2FGFR3MAP4K3IRAK1
SCHEMBL986724 0.85 GRK5 (0.39) FGFR1FGFR2FGFR3MAP4K3KCNN4
SCHEMBL4406224 0.84 FGFR1 (0.48) FGFR1FGFR2FGFR3MAP4K3MAP4K1
SCHEMBL4404805 0.84 FGFR1 (0.46) FGFR1FGFR2FGFR3MAP4K3MAP4K1
SCHEMBL4404813 0.84 FGFR1 (0.46) FGFR1FGFR2FGFR3MAP4K3MAP4K1
SCHEMBL4408489 0.84 FGFR1 (0.46) FGFR1FGFR2FGFR3MAP4K3MAP4K1
SCHEMBL4412646 0.81 ATR (0.34) FGFR1FGFR2FGFR3ATRMAP4K3
SCHEMBL4412495 0.79 FGFR1 (0.42) FGFR1FGFR2FGFR3MAP4K3
SCHEMBL4405400 0.79 FGFR1 (0.42) FGFR1FGFR2FGFR3MAP4K3
SCHEMBL4406304 0.79 FGFR1 (0.42) FGFR1FGFR2FGFR3MAP4K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101479255-B C-MET protein kinase inhibitors for the treatment of proliferative disorders VERTEX PHARMA 2013-05-01 — — CN claimed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 — — EP claimed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 — — US claimed
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 — — US disclosed
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 — — US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 — — US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 — — US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 FGFR1 285/4885FGFR2 323/4885FGFR3 249/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 FGFR1 285/4885FGFR2 323/4885FGFR3 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.